|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.07/0.05
|
企业价值
261.64M
|
资产负债 |
每股账面净值
0.38
|
现金流量 |
现金流量率
0.03
|
损益表 |
收益
83.57M
|
每股收益
1.11
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/29 12:06 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment. |